 NEW YORK, June 15, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today highlighted data from its pivotal Phase 3 SIERRA trial for Iomab-B in an oral presentation at the 2021 Society of Nuclear Medicine and Molecular Imaging SNMMI Annual Meeting, which is being held virtually from June 11 th 14th. Iomab-B is radiotherapy that targets cells expressing CD45, a protein found only on blood cancer cells and immune cells including bone marrow stem cells, with the radioisotope iodine-131 and is intended to be a targeted conditioning agent to enable potentially curative bone marrow transplant BMT. 